Eptaplatin

Drug Profile

Eptaplatin

Alternative Names: Heptaplatin; NSC 644591; NSC D 644591; SKI 2053R; Sunpla

Latest Information Update: 18 Sep 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SK Pharma
  • Class Antineoplastics; Platinum complexes; Small molecules
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Cancer

Most Recent Events

  • 18 Sep 2001 A phase I study has been added to the Cancer pharmacokinetics and adverse events sections
  • 02 Dec 1999 A study has been added to the therapeutic trials and adverse events sections
  • 24 Nov 1999 First global launch in Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top